Powder: -20°C for 3 years | In solvent: -80°C for 1 year
CTS-1027 is a small molecule inhibitor of MMPs (IC50s: 0.3 nM, 0.5 nM for MMP2, MMP13). It has < 1,000 fold selectivity over MMP1.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
2 mg | 5 days | $ 97.00 |
Description | CTS-1027 is a small molecule inhibitor of MMPs (IC50s: 0.3 nM, 0.5 nM for MMP2, MMP13). It has > 1,000 fold selectivity over MMP1. |
Targets&IC50 | MMP2:0.2 nM, MMP3:9.5 nM, MMP14:15 nM, MMP8:0.9 nM, MMP13:0.5 nM, MMP12:0.7 nM |
In vivo | CTS-1027 improves overall animal survival following 14 days of BDL in mice [1]. CTS-1027 effectively reduces features of cholestatic liver injury, the hepatocyte apoptosis, and markers of hepatic fibrogenesis in the BDL mouse. The terminal plasma concentration of RS-130830 is 311 nM, in male animals treated for 8 weeks. RS-130830(8 weeks; male mice ) treatment causes an 89% increase in plasma triglyceride concentration. But there is no corresponding effect in female mice treated for 12 weeks. The plaque lipid content of animals receiving RS-130830 is increased by 81% at 12 weeks, and increased by 41% at 16 weeks [2]. |
Synonyms | RS 130830, Ro 1130830 |
Molecular Weight | 425.88 |
Formula | C19H20ClNO6S |
CAS No. | 193022-04-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 100 mg/mL (234.81 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
CTS-1027 193022-04-7 Others RS 130830 Ro 1130830 RS130830 CTS1027 RS-130830 CTS 1027 inhibitor inhibit